Feasibility of Evaluating Gene Alteration Analysis Using Samples Obtained by EBUS-TBNA in Patients With Lung Cancer
Lung cancer is the leading cause of death in the world. Overall 5-year survival rate is
fewer than 10% and the effectiveness of conventional chemotherapy is limited. The new
knowledge shows the correlation between genetic alteration and effective of chemotherapy.
Therefore non-surgical modalities to obtain tumour specimens for genetic alteration analysis
are particularly critical in lung cancer, since many patients have advanced disease at the
time of first presentation, and are therefore not eligible for radical surgery.
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) samples
obtained during diagnosis of lung cancer can be used for molecular analysis that will
predict response to treatment and prognosis. In this study, we will detect specific target
molecules related to the effectiveness of treatment (surgery, chemotherapy, radiation therapy)
and prognosis in patients with lung cancer using EBUS-TBNA samples and its combined with
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society